1) Demodex Blepharitis: An Overview

What it is & why it matters.
Demodex blepharitis (DB) is an eyelid margin disease caused by Demodex mites (primarily D. folliculorum and D. brevis) and is frequently under-recognized in general eye-care settings. The presence of collarettes (cylindrical dandruff) at the lash base is pathognomonic and should be assessed on downward gaze at the slit lamp. Population-level clinic data suggest collarettes are common among all-comers, not just patients with classic risk profiles. PMC+2PMC+2

Clinical impact.
DB contributes to eyelid margin inflammation, meibomian gland dysfunction (MGD), and evaporative dry eye, and it can persist despite standard anti-inflammatory dry-eye therapy—hence the importance of inspecting for collarettes specifically. subspecialtyday.ascrs.org+1

Diagnosis (chairside).

• Look for waxy collarettes anchored to the lash base (not migrating up the shaft like bacterial debris).

• Grade collarette burden and lid erythema; consider lash epilation only if needed for confirmation. PMC

Treatment—what’s changed.

• Lotilaner 0.25% ophthalmic solution (XDEMVY) is FDA-approved for DB (BID x 6 weeks). In Saturn-1 and Saturn-2, lotilaner significantly reduced collarettes and mite density and was generally well tolerated. Pooled analyses reinforce safety/efficacy. ir.tarsusrx.com+4PubMed+4PubMed+4

• Adjuncts/legacy approaches: lid hygiene, in-office micro-exfoliation, and TTO/terpinen-4-ol–based cleansers have been used historically, but tolerability is variable and evidence is weaker relative to lotilaner. Follow contemporary blepharitis PPP guidance. AJMC

Clinic pearls.

• Train techs to “look down, find the collars.” Document collarette grade in every DED/MGD workup.

• If collarettes are present, treat DB directly rather than escalating only anti-inflammatories; re-check at 6–8 weeks post-therapy. PMC

2) Exploring the Use of Ivermectin for “Dry Eyes”

Scope of evidence.
Most ivermectin data in eye care address Demodex-associated blepharitis, not idiopathic DED. Small studies (prospective series and RCTs) of topical ivermectin 1% cream applied to the lid margin (off-label) show reduced collarettes/mite counts and symptomatic improvement; some reports evaluate ivermectin–metronidazole combinations or protocols paired with IPL. Robust RCT evidence for ivermectin in non-Demodex dry eye is lacking. PubMed+4PMC+4ScienceDirect+4

Potential upsides.

• Antiparasitic effect on Demodex with improvement in blepharitis signs; several studies report better MGD secretion quality after regimens that include ivermectin. PubMed

Drawbacks & cautions.

• Off-label for eyelid use; avoid ocular surface contact. Reported adverse effects include local irritation/burning.

• Data are heterogeneous (dosing frequency from weekly to monthly courses, combo products, variable follow-up).

• No high-quality trials for ivermectin in DED without Demodex—any “dry eye” benefit likely reflects DB control rather than a primary tear-film effect. (Inference based on literature focus; no RCTs identified for non-Demodex DED.) PMC+1

Practical take.
If you confirm DB (collarettes present) and lotilaner is unavailable or contraindicated, some clinicians consider a short, carefully instructed off-label ivermectin course on the external lid margin—with informed consent and strict avoidance of the ocular surface. For most patients, lotilaner remains the evidence-based, on-label first-line. PubMed+1

3) Understanding Melasma: Causes, Symptoms, and Treatment (Ocular Aesthetics Series)

What you’ll see.
Melasma presents as symmetric, reticulated hyperpigmented macules/patches on photoexposed facial areas (malar, centrofacial, mandibular patterns) and can extend periocularly. UV and visible light exposure, hormonal influences (pregnancy/OCPs), genetics, and heat contribute to pathogenesis. NCBI+1

First principles of management.

• Rigorous photoprotection is foundational. For melasma and other dyschromias—especially in skin of color—tinted, iron-oxide–containing sunscreens provide visible-light coverage and reduce relapse compared with non-tinted formulas. Recommend daily use and re-application for all patients pursuing periocular aesthetic procedures. PubMed+2Wiley Online Library+2

• Topical depigmenting therapy: hydroquinone (often in triple-combination with tretinoin + fluocinolone), azelaic acid, kojic acid, cysteamine, thiamidol; topical tranexamic acid (TXA) is increasingly used. Frontiers

• Systemic/adjunct: oral TXA (typically 250 mg BID for 8–12+ weeks) improves MASI scores in multiple studies; screen carefully for thromboembolic risk and counsel on off-label use. Newer data suggest topical TXA may approach oral efficacy over 12 weeks in some cohorts. PMC+2Lippincott Journals+2

Devices—set expectations & proceed cautiously.

• IPL and lasers can provide short-term improvement in selected patients when combined with strict photoprotection and topical regimens; however, recurrence rates are high, and PIH and rebound are documented—particularly with Q-switched lasers and in higher Fitzpatrick types. Many dermatology reviews emphasize cautious, tailored use rather than first-line reliance. MDPI

• When treating periocular skin for other indications (vascularity, lentigines, “skin tightening”), avoid targeting melasma directly with IPL, especially in Fitzpatrick IV–VI; prioritize medical therapy and photoprotection first. (Clinical caution aligned with evidence on relapse/PIH and variable IPL outcomes.) MDPI

Quick counseling script for your aesthetics patients.
“Melasma is light-sensitive and relapses. We’ll start with medical therapy and a tinted, iron-oxide SPF to block UV and visible light. We generally don’t use IPL as first-line on melasma because of relapse and PIH risk; if we consider devices later, it’s with strict prep, conservative parameters, and ongoing topical maintenance.” PubMed+1

References (selected)

1. Trattler W, Karpecki P, et al. Prevalence of Demodex blepharitis… Clin Ophthalmol. 2022. Collarettes are pathognomonic and common in clinic populations. PMC

2. Rhee MK, Yeu E, et al. Demodex blepharitis: comprehensive review. Eye Contact Lens. 2023. Practical diagnosis/management updates. PMC

3. Yeu E, Wirta DL, Karpecki P, et al. Saturn-1. Cornea. 2023. Lotilaner 0.25% pivotal RCT. PubMed

4. Gaddie IB, Donnenfeld ED, Karpecki P, et al. Saturn-2. Ophthalmology. 2023. Lotilaner 0.25% pivotal RCT. PubMed

5. Syed YY. Lotilaner 0.25%: First approval. Drugs. 2023. Regulatory context. PMC

6. Choi Y, et al. Topical ivermectin 1% for ocular demodicosis. 2021. PMC

7. Ávila MY, et al. Ivermectin-metronidazole gel RCT. Cont Lens Anterior Eye. 2021/2024. ScienceDirect+1

8. Salazar JR, et al. Monthly ivermectin 1% cream series. Cornea Open. 2024. Lippincott Journals

9. Combined ivermectin + IPL observational outcomes. 2024. PubMed

10. Fatima S, et al. Sunscreen and visible light in melasma/PIH. 2020. PMC

11. Dumbuya H, et al. Iron-oxide formulations protect vs visible light. 2020. PubMed

12. Jiryis B, et al. Laser & light therapies in melasma (review). J Clin Med. 2024. (Recurrence/PIH risks; cautious use.) MDPI

13. Godse K, et al. Oral TXA in melasma (review). 2023. PMC

14. Heidary B, et al. Oral vs topical TXA RCT. 2025. PMC